It was an absolute pleasure to speak with Prof. Mariana Castells (Brigham and Women’s Hospital, Boston, MA) about her study of BLU-263 and how it is supporting continued development for patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome.
The abstract entitled ‘A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome’ (Abstract #665) was presented at The American Academy of Allergy, Asthma & Immunology (AAAAI), February 25-28, 2022
Questions:
- What is BLU-263 and what is the rationale for its use in this patient population?(0:25)
- What are the aims and design of the HARBOR study?(02:26)
- What are the eligibility criteria of the study?(03:51)
- When are the initial results expected?(05:12)
Disclosures: Mariana Castells has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual AAAAI 2022.
